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Abstract
Introduction: The prevalence of metabolic syndrome increases after menopause; however, the role of concomitant subclinical hypo-
thyroidism has not been completely elucidated. The aim of the study was to identify associations between thyrotropin, immune status, 
inflammation, and metabolic syndrome in postmenopausal women.
The specific goals were: to assess thyrotropin (TSH) and interleukin-6 (IL-6) concentrations in the serum of subclinical hypothyroid post-
menopausal women with and without metabolic syndrome and compare them with euthyroid controls; to test whether immune status is 
related to metabolic syndrome in postmenopausal women and determine the role of IL-6; to examine the relationships between TSH and 
different features of metabolic syndrome: insulin resistance, waist circumferences, waist-to-hip ratio (WHR), BMI, metabolic parameters 
(triglycerides, total cholesterol and high-density lipoprotein cholesterol), and inflammatory cytokines (IL-6).
Material and methods: Three hundred and seventy-two postmenopausal women were included in the study: 114 women had subclini-
cal hypothyroidism (10.0 uIU/mL > TSH ≥ 4.5 uIU/mL, normal fT4), and 258 women were in euthyreosis (TSH 0.35–4.5 uIU/mL, normal 
fT4); both groups were matched by age. Anthropometric measurements were conducted (BMI, waist circumference, WHR) and blood 
pressure was measured. In all subjects the following were assessed in serum: lipid profile, glucose, insulin, TSH, fT4, thyroid antibodies 
(T-Abs) — TPO-Abs, TG-Abs, and IL-6 concentrations.
Results: The prevalence of metabolic syndrome was 49.12% in subclinical hypothyroid women and 46.89% in euthyroid women. However, 
the proportion of subjects with one or two abnormalities was significantly higher in the subclinical hypothyroid group (45.61%) than 
in the euthyroid group (32.17%). When we compared subclinical hypothyroid women with and without metabolic syndrome, subjects 
with metabolic syndrome had higher BMI, abdominal circumferences, WHR, and HOMA-I. They presented higher systolic and diastolic 
blood pressure. Serum concentrations of cholesterol, triglycerides, fasting glucose, IL-6, TSH, T-Abs were also higher and serum cHDL 
was lower. There were no significant differences in fT4 concentrations. A similar comparison was made for euthyroid women with and 
without metabolic syndrome. Higher BMI, waist circumference, WHR, HOMA-I, and systolic blood pressure were observed in subjects 
with metabolic syndrome. Serum concentrations of TSH, triglycerides, glucose, and IL-6 were also higher, but the concentration of cHDL 
was significantly lower. There were no significant differences in fT4, T-Abs, cholesterol levels, and diastolic pressure. 
When we compared euthyroid women T-Abs (+) and T-Abs (–), the prevalence of metabolic syndrome was similar (48.68% vs. 46.15%). 
There were no differences in BMI, waist circumference, WHR, lipid profile, glucose, and HOMA-I, fT4. However, thyroid autoimmunity 
was associated with elevated TSH and IL-6 levels. When we analysed subclinical hypothyroid women with and without thyroid autoim-
munity, there were no significant differences in glucose and lipid profile. However, Hashimoto`s subjects were more obese, had higher 
waist circumference, WHR, HOMA-I, and higher prevalence of metabolic syndrome. Serum concentrations of TSH and IL-6 were also 
higher and fT4 was lower. 
Among all of the women, serum TSH concentration was significantly correlated with BMI, waist circumference, WHR, systolic blood 
pressure, cholesterol, triglycerides, and TPO-Abs. When the variables of subjects with upper quartile of TSH were compared with lower 
quartile of TSH, we found significantly higher BMI, waist circumference, WHR, increased concentration of IL-6, cholesterol, triglycerides, 
and T-Abs, and concentrations of cHDL and fT4 were lower. OR for metabolic syndrome in subjects with upper quartile TSH vs. lower 
quartile was 1.35 (95% confidence interval [CI] 1.10–1.60). 
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overt hypothyroidism and metabolic syndrome are well 
described, but it remains controversial whether subclinical 
hypothyroidism also leads to higher cardiovascular risk 
and metabolic syndrome. The results of studies examining 
these connections are contradictory. A series of studies 
reported that subclinical hypothyroidism is associated 
with abnormal serum lipids, higher blood pressure, and 
markers of systemic inflammation [1, 2]. However, few 
studies have excluded the potential influence of subclinical 
hypothyroidism on metabolic syndrome [3]. 
The most common cause of hypothyroidism is 
autoimmune thyroiditis (AIT), a condition associated 
Conclusions: 
1. Our study confirms that metabolic syndrome in both euthyroid and subclinical hypothyroid women is connected with obesity, 
visceral fat accumulation, and higher TSH and IL-6 concentrations. 
2. Immune thyroiditis is associated with higher TSH and IL-6 levels. Obese subclinical hypothyroid women with Hashimoto`s thyroditis 
have a higher prevalence of metabolic syndrome when compared with subclinical hypothyroid women without thyroid autoimmunity. 
3. It is possible that in the crosstalking between subclinical hypothyroidism and metabolic syndrome, enhanced proinflammatory 
cytokine release in the course of immunological thyroiditis plays a role.
(Endokrynol Pol 2015; 66 (5): 394–403)
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Streszczenie
Wstęp: Nie jest do końca poznana rola subklinicznej niedoczynności tarczycy w patogenezie zespołu metabolicznego u kobiet po me-
nopauzie. Celem pracy jest ocena powiązań pomiędzy zespołem metabolicznym, stanem tyreometabolicznym, autoimmunologicznym 
zapaleniem tarczycy i stanem zapalnym u kobiet po menopauzie.
Szczegółowe cele pracy to: ocena stężenia TSH, interleukiny-6 (IL-6) u kobiet po menopauzie z subkliniczną niedoczynnością tarczycy, 
z zespołem i bez zespołu metabolicznego oraz porównanie z grupą kontrolną w eutyreozie; określenie czy immunologiczne zapalenie 
tarczycy ma wpływ na rozwój zespołu metabolicznego oraz określenie roli IL-6; sprawdzenie zależności między TSH i składowymi zespołu 
metabolicznego: opornością insulinową, parametrami antropometrycznymi, metabolicznymi i cytokinami zapalnymi (IL-6). 
Materiał i metody: Do badania włączono 372 kobiety po menopauzie: 114 kobiet z rozpoznaną subkliniczną niedoczynnością tarczycy 
(10,0 uIU/ml > TSH ≥ 4,5 uIU/ml, przy prawidłowym fT4) i 258 kobiet z eutyreozą (TSH 0,35–4,5 uIU/ml, prawidłowe fT4). Grupy nie 
różniły się wiekowo. Przeprowadzono pomiary antropometryczne (BMI, obwód w talii, WHR) oraz ciśnienia tętniczego. U wszystkich 
badanych oceniano we krwi: profil lipidowy, stężenie glukozy, insuliny, TSH, fT4, przeciwciał tarczycowych — TPO-Ab, TG-Ab oraz IL-6.
Wyniki: Częstość występowania zespołu metabolicznego wynosiła 49,12% u kobiet z subkliniczną niedoczynnością tarczycy i 46,89% 
u kobiet w eutyreozie. Jednakże w grupie z subkliniczną niedoczynnością, w porównaniu do kobiet w eutyreozie, u większego odsetka 
rozpoznano jedną lub też dwie składowe zespołu metabolicznego (45,61% vs. 32,17%). Gdy kobiety z subkliniczną niedoczynnością 
i zespołem metabolicznym porównano z kobietami bez zespołu, stwierdzono wyższe BMI, obwód w talii, WHR, HOMA-I, wyższe ciśnie-
nie tętnicze skurczowe i rozkurczowe, wyższe stężenie cholesterolu, triglicerydów, glukozy, IL-6, TSH, przeciwciał przeciwtarczycowych 
i niższe stężenie cholesterolu frakcji HDL. Nie obserwowano natomiast różnic w stężeniu fT4. Gdy tą samą analizę przeprowadzono 
u kobiet w eutyreozie, również stwierdzono u osób z zespołem metabolicznym wyższe: BMI, obwód w talii, WHR, HOMA-I i skurczowe 
ciśnienie tętnicze. Stężenia TSH, triglicerydów, glukozy, IL-6 były znamiennnie wyższe, a cholesterolu frakcji HDL niższe. Nie było różnic 
w stężeniu fT4, przeciwciał przeciwtarczycowych, cholesterolu i ciśnieniu rozkurczowym.
Gdy porównano kobiety w eutyreozie z immunologicznym zapaleniem i bez zapalenia, częstość występowania zespołu metabolicznego 
była podobna (48,68% vs. 46,15%). Nie było różnic w BMI, obwodzie talii, WHR, profilu lipidowym, glukozie, HOMA-I, fT4. Jednakże 
w przewlekłym zapaleniu tarczycy obserwowano podwyższone stężenia TSH i IL-6. Gdy analizowano kobiety z subkliniczną niedo-
czynnością oraz bez autoimmunologicznego zapalenia, nie stwierdzono różnic w stężeniu glukozy i profilu lipidowym. Jednakże kobiety 
z chorobą Hashimoto miały wyższe BMI, trzewne gromadzenie tkanki tłuszczowej, wyższy HOMA-I oraz częściej występował u nich 
zespół metaboliczny. Stężenie TSH, IL-6 były wyższe, a fT4 niższe. 
Wśród wszystkich badanych kobiet stężenie TSH dodatnio korelowało z BMI, obwodem talii, WHR, ciśnieniem skurczowym, chole-
sterolem, triglicerydami, TPO-Ab. Gdy porównano analizowane parametry u kobiet z górnego i dolnego kwartyla TSH, stwierdzono 
wyższe BMI, obwód w talii, WHR, podwyższone stężenie IL-6, cholesterolu, triglicerydów i przeciwciał przeciwtarczycowych, natomiast 
stężenie cholesterolu frakcji HDL i fT4 było niższe. Iloraz szans (OR) wystąpienia zespołu metabolicznego u kobiet z TSH > 4,68 uIU/ml 
w porównaniu z osobami z TSH < 1,82 uIU/ml wynosiło 1,35.
Wnioski: 
1. Zespół metaboliczny zarówno u kobiet w eutyreozie, jak i z subkliniczną niedoczynością, jest powiązany z otyłością, trzewnym 
gromadzeniem tkanki tłuszczowej oraz wyższym stężeniem TSH i IL-6. 
2. W autoimmunologicznym zapaleniu tarczycy stężenia TSH i IL-6 są podwyższone.
3. Otyłe kobiety z subkliniczną niedoczynnością tarczycy w przebiegu choroby Hashimoto są bardziej narażone na ryzyko rozwoju 
zespołu metabolicznego. 
4. Ogniwem łączącym subkliniczną niedoczynność tarczycy i zespół metaboliczny mogą być cytokiny zapalne. 
 (Endokrynol Pol 2015; 66 (5): 394–403)
Słowa kluczowe: zespół metaboliczny; subkliniczna niedoczynność; autoimmunologiczne zapalenie tarczycy; interleukina-6
Introduction
The development of metabolic syndrome significantly 
increases in women after menopause. All its components 
including abdominal obesity, abnormal lipids, insulin 
resistance, and hypertension are the result mainly of 
ovarian failure. However, with age, increasing incidence 
of overt and subclinical hypothyroidism is observed, 
and this dysfunction also promotes weight gain, lipid 
disturbances, hypertension, and atherosclerosis. Metabolic 
changes in hypothyroidism are analogous to those ob-
served in metabolic syndrome. The associations between 
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with the infiltration of thyroid by lymphocytes and 
other immune cells. This may result in the develop-
ment of thyroid dysfunction; however, the progression 
towards overt hypothyroidism is usually a gradual 
process, taking several years. In the early stage, thyroid 
stimulating hormone (TSH) levels may be within the 
reference range, and in the evolution from normal to 
abnormal thyroid function subclinical hypothyroidism 
may develop [4]. It is suggested that AIT is connected 
with higher cardiovascular risk independent of thy-
roid function. Chronic inflammation and endothelial 
dysfunction could be a link. Different cytokines and 
adhesion molecules are involved in the pathogenesis 
of AIT, working in both the immune system and the 
thyroid gland. They are known to modify epithelium 
integrity and allow the infiltration of thyroid by T cells 
and other immune cells. Interleukin-6 (IL-6) has been 
identified as one of the markers of systematic inflam-
mation. Some researchers have found increased serum 
concentrations of IL-6 in Hashimoto`s thyroiditis [5, 6]. 
Because postmenopausal women with metabolic 
syndrome displayed higher serum IL-6 concentrations 
[7], we decided to investigate the relationships between 
IL-6, metabolic syndrome, AIT, and subclinical hypothy-
roidism. There are few studies regarding the prevalence 
of metabolic syndrome in postmenopausal women with 
subclinical hypothyroidism in the Polish population, 
and they do not explain whether thyroid failure and 
AIT have independent effects on metabolic syndrome 
in this population. Therefore, we undertook the present 
study to determine the association between thyroid 
function, autoantibodies to thyroid-specific antigens, 
and metabolic syndrome in Polish postmenopausal 
women. The study was conducted in the Silesian region. 
The specific goals were:
 — to assess TSH and IL-6 concentrations in the serum 
of subclinical hypothyroid postmenopausal women 
with and without metabolic syndrome and compare 
them with euthyroid controls;
 — to test whether immune status is related to meta-
bolic syndrome in postmenopausal women and 
determine the role of IL-6;
 — to examine the relationships between TSH and 
different features of metabolic syndrome: insulin 
resistance, waist circumferences, waist-to-hip ratio 
(WHR), BMI, metabolic parameters (triglycerides, 
total cholesterol, and high density lipoprotein cho-
lesterol), and inflammatory cytokines (IL-6).
Material and methods
Three hundred and seventy-two postmenopausal women 
were included into the study: 114 women had subclinical 
hypothyroidism and 258 women were in euthyreosis, both 
groups were matched by age. We included women re-
cruited from endocrinological and cardiological outpatient 
clinics, with age at least 55 years or without natural menses 
for at least five years. All the subjects who participated in 
the study gave their agreement in the written form. The 
study was approved by the Ethical Review.
The group of subclinical hypothyroidism included 
women with elevated serum TSH concentration above 
4.5 uIU/mL but lower than 10 mIU/mL, whereas serum 
free thyroxine (fT4) was normal. At the moment of inclu-
sion into the study no treatment of subclinical hypothy-
roidism was started. The mean age was 59.18 years (SD 
5.64). The euthyroid group included participants with 
mean age 58.93 years (SD 5.78). The euthyroid status 
was confirmed by normal TSH (0.35–4.5 uIU/mL) and 
normal fT4. 
Exclusion criteria of both groups were: diagnosis of 
coronary artery disease, diabetes mellitus, heart, renal, 
or liver failure. Women taking thyroxine, amiodarone, 
lipid-lowering, and antidiabetes drugs were excluded 
from the study. In all subjects medical history was 
evaluated, physical examination was performed, and 
blood pressure was measured. Anthropometric meas-
urements were conducted. BMI was calculated as the 
ratio of weight to the square of height, and WHR was 
calculated by division of the circumferences of waist and 
hip. Blood samples were obtained in fasting condition 
and after centrifuging the serum were stored at –70oC 
until assay. In all subjects lipid profile (total cholesterol, 
HDL cholesterol, triglycerides) and glucose concentra-
tions were assessed using enzymatic method. Serum 
insulin, TSH, fT4, thyroid autoantibodies, and IL-6 were 
determined by ELISA methods using commercial assays. 
AIT was defined as the presence of elevation of at least 
one of the antithyroid antibodies (T-Abs) — thyreoper-
oxidase antibodies (TPO-Abs), thyroglobulin antibodies 
(TG-Abs), and the presence of typical thyroid sonogra-
phy (heterogenous echotexture or hypoechogenicity). 
The homeostatic model assessment (HOMA) index 
was calculated (HOMA-IR = fasting serum glucose 
(mg/dL)/18.1 × fasting insulin levels (uIU/mL)/22.5). The 
diagnosis of metabolic syndrome was performed using 
the AHA/NHLBI criteria (it was defined as the presence 
of three or more of the following: waist circumference 
≥ 88 cm, serum triglycerides ≥ 1.7 mmol/L, serum cHDL 
< 1.3 mmol/L, fasting glucose ≥ 5.6 mmol/L, elevated 
blood pressure ≥ 130/85 mm Hg). Data were tested for 
normal distribution using W Shapiro-Wilk test. Results 
were given as mean and SD for normally distributed data 
or median plus (25th, 75th) percentiles for non-normal 
distribution. Groups were compared by Student`s test 
or U Manna-Whitney test. Correlations between vari-
ables were estimated by calculating the correlation coef-
ficient R by Pearson`s method or Spearman`s method. 
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Univariable logistic regression model (odds ratio, OR) 
was used to evaluate the association between metabolic 
syndrome and different metabolic and inflammatory 
variables. ANOVA trend analysis was used to evaluate 
means of metabolic and inflammatory factors according 
quartiles of TSH. The prevalence of metabolic syndrome 
and its components were compared using chi-squared 
test. Statistical analysis was performed using Statistica 
version 10, StatSoft Inc.
Results
In the first part of the study we analysed the data from 
all 372 postmenopausal women according to the thyroid 
status (hypothyroid, euthyroid). The characteristics 
of the subjects are summarised in Table I. The mean 
age of the postmenopausal subclinical hypothyroid 
subjects was approximately 59.18 ± 5.64 years and 
was similar to euthyroid women (58.93 ± 5.78 years). 
The mean BMI in subclinical hypothyroid group was 
29.61 ± 5.07, being slightly higher in comparison to 
euthyroid women (28.77 ± 5.01), but the difference did 
not reach statistical difference (p = 0.10). However, waist 
circumference and WHR were significantly higher in 
the subclinical hypothyroid group, p < 0.05. As shown 
in Table I, the levels of total cholesterol, triglycerides, 
TSH, and T-Abs were higher and fT4 were lower in the 
subclinical hypothyroid group than in the euthyroid 
group. Mean systolic and diastolic blood pressures were 
higher in the subclinical hypothyroid group compared 
with the euthyroid group. Statistical analysis showed 
that there were no significant differences in glucose, 
HOMA-I, HDL cholesterol, and IL-6 concentrations 
between those groups. 
In the next step we compared the frequencies of 
analysed risk factors among subclinical hypothyroid 
women and euthyroid women (Table II). Positive 
thyroid antibodies were detected in 73 (64.03%) sub-
clinical hypothyroid postmenopausal women and in 
76 (29.46%) euthyroid women. The prevalence of hav-
ing at least three MS diagnostic criteria were met in 
121 (46.89%) euthyroid and in 56 (49.12%) subclinical 
hypothyroid women, respectively, p = NS. 
The proportion of subjects with one or two abnor-
malities was significantly higher in the subclinical 
hypothyroid group (45.61%) than in the euthyroid 
group (32.17%). The prevalence of subjects without risk 
factors was significantly higher in euthyroid women 
(20.93%) when compared with the subclinical hypo-
thyroid group (5.26%) (Table II). 
Assessment of analysed variables in euthyroid 
and subclinical hypothyroid women with and 
without metabolic syndrome 
Then we compared subclinical hypothyroid women 
with and without metabolic syndrome (Table III). 
Table I. Clinical and biochemical characteristics of subclinical hypothyroid and euthyroid postmenopausal women 
Tabela I. Porównanie klinicznych i biochemicznych cech wśród kobiet po menopauzie z subkliniczną niedoczynnością tarczycy 
i eutyreozą
Euthyroid wome (n = 258) Subclinical hypothyroid women (n = 114) p
Age 58.93 ± 5.78 59.18 ± 5.64 NS
BMI [kg/m2] 28.77 ± 5.01 29.61 ± 5.07 0.10
Waist circumference [cm] 93.36 ± 12.41 95.76 ± 12.89 < 0.05
WHR 0.86 ± 0.06 0.87 ± 0.07 < 0.05
Cholesterol [mmol/L] 6.06 ± 1.20 6.35 ± 0.99 < 0.01
cHDL [mmol/L] 1.35 ± 0.37 1.30 ± 0.38 NS
Triglycerides [mmol/L] 1.63 ± 0.84 1.74 ± 0.80 < 0.05
Glucose [mg/dL] 90.80 ± 19.42 86.91 ± 14.88 NS
HOMA-IR 1.03 [0.64; 1.87] 1.10 [0.60; 2.12] NS
IL-6 [pg/mL] 3.0 [2.37; 3.91] 2.95 [2.17; 4.25] NS
TSH [mIU/mL] 2.15 ± 0.86 5.45 ± 0.90 < 0.001
fT4 [ng/dL] 1.32 ± 0.66 [1.22] 1.14 ± 0.58 [1.18] < 0.01
TPOAb [IU/mL] 6.03 [2.36; 46.40] 65.29 [7.63; 145.0] < 0.001
TGAb [IU/mL] 20.22 [16.35, 27.04] 53.86 [42.29, 156.04] < 0.01
Systolic blood pressure [mm Hg] 128.48 ± 25.51 138.74 ± 34.29 < 0.01
Diastolic blood pressure [mm Hg] 80.56 ± 18.62 86.81 ± 22.92 < 0.05
Normally distributed data are given as mean ± SD, skewed data are given as median plus [25th, 75th] percentiles. The significance tests are the Mann-Whitney U test 
for normally distributed variables and unpaired t test for normally distributed variables.
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Women with metabolic syndrome had higher BMI, 
abdominal circumferences, WHR, and HOMA-I. They 
presented higher systolic and diastolic blood pressure. 
Serum concentrations of cholesterol, triglycerides, 
fasting glucose, IL-6, TSH, and T-Abs were also higher 
and serum cHDL was lower. There were no significant 
differences in fT4 concentrations. A similar comparison 
was made for euthyroid women with and without 
metabolic syndrome. Higher BMI, waist circumfer-
ence, WHR, HOMA-I, and systolic blood pressure were 
observed in subjects with metabolic syndrome. Serum 
concentrations of TSH, triglycerides, glucose, and IL-6 
were also higher, but the concentration of cHDL was 
significantly lower. There were no significant differen-
ces in fT4, T-Abs, cholesterol levels, and diastolic pres-
sure (Table III). 
Effect of thyroid autoimmunity
To assess the potential effects of immunological thy-
roiditis, we performed a subgroup analysis according 
to the presence or absence of thyroid antibodies, after 
separating postmenopausal patients, just as subclinical 
hypothyroid and euthyroid (Table IV). The proportion 
of subjects with T-Abs (+) was higher in the subclinical 
hypothyroid group than in the euthyroid group (57.89% 
vs. 29.46%). When we compared euthyroid women’s 
T-Abs (+) and T-Abs (–), the prevalence of metabolic 
syndrome was similar (48.68% vs. 46.15%). There were 
Table II. Comparison of risk factor frequencies in euthyroid and subclinical hypothyroid postmenopausal women 
Tabela II. Porównanie częstości występowania czynnika ryzyka wśród kobiet po menopauzie w eutyreozie i z subkliniczną 
niedoczynnością tarczycy
Euthyroid women (n = 258) Subclinical hypothyroid women (n = 114) p
Without risk factors, n (%) 54 (20.93%) 6 (5.26%) < 0.001
One or two risk factors, n (%) 83 (32.17%) 52 (45.61%) < 0.01
Three or more risk factors = metabolic syndrome, n (%) 121 (46.89%) 56 (49.12%) NS
antiTPO and/or antiTGAb positivity, n (%) 76 (29.46%) 73 (64.03%) < 0.001
Table III. Comparison of clinical and biochemical characteristics of euthyroid and subclinical hypothyroid postmenopausal 
women with and without metabolic syndrome
Tabela III. Porównanie klinicznych i biochemicznych cech wśród kobiet po menopauzie w eutyreozie i z subkliniczną 
niedoczynnością tarczycy z i bez zespołu metabolicznego
Euthyroid women (n = 258) Subclinical hypothyroid women (n = 114)
Nonmetabolic 
women (n = 137)
Women with metabolic 
syndrome (n = 121)
p Nonmetabolic 
women (n = 58)
Women with metabolic 
syndrome (n = 56)
p
BMI [kg/m2] 26.81 ± 4.5 30.99 ± 4.6 < 0.001 27.34 ± 3.88 31.95 ± 5.12 < 0.001
Waist circumference [cm] 88.1 ± 12.16 99.28 ± 9.7 < 0.001 89.33 ± 10.21 102.45 ± 12.02 < 0.001
WHR 0.83 ± 0.05 0.88 ± 0.05 < 0.001 0.84 ± 0.06 0.90 ± 0.06 < 0.001
Cholesterol [mmol/L] 5.99 ± 1.11 6.13 ± 1.30 NS 6.08 ± 0.77 6.63 ± 1.12 < 0.01
Cholesterol HDL [mmol/L] 1.52 ± 0.35 1.15 ± 0.29 < 0.001 1.47 ± 0.33 1.13 ± 0.35 < 0.001
Triglycerides [mmol/L] 1.26 ± 0.54 2.03 ± 0.93 < 0.001 1.32 ± 0.42 2.17 ± 0.86 < 0.001
Glucose [mg/dL] 84.72 ± 11.13 97.87 ± 23.93 < 0.001 81.64 ± 12.52 92.37 ± 15.26 < 0.001
HOMA-IR 0.79 [0.54; 1.14] 1.72 [0.94; 2.91] < 0.001 0.67 [0.46; 1.11] 1.88 [1.08; 3.28] < 0.001
IL-6 [pg/mL] 2.85 [2.17; 3.36] 3.15 [2.66; 4.50] < 0.01 2.55 [2.04; 2.97] 3.69 [2.63; 5.01] < 0.001
TSH [mIU/mL] 2.01 ± 0.77 2.38 ± 0.95 < 0.01 5.21 ± 0.74 5.68 ± 0.97 < 0.01
fT4 [ng/dL] 1.37 ± 0.59 1.32 ± 0.66 NS 1.14 ± 0.58 1.19 ± 0.68 NS
TPOAb [IU/mL] 5.65 [2.11; 46.58] 6.57 [2.47; 34.7] NS 12.24 [2.01; 108.2] 125.84 [18.89; 191.69] < 0.001
TGAb [IU/mL] 18.15 [12.79; 35.2] 20.22 [16.35, 27.04] NS 42.75 [13.64; 56.04] 79.46 [27.34; 146.79] < 0.01
Systolic blood pressure  
[mm Hg]
124.52 ± 26.74 131.17 ± 29.53 < 0.01 130.31 ± 20.86 139.55 ± 38.34 < 0.01
Diastolic blood pressure 
[mm Hg]
80.64 ± 13.70 82.44 ± 18.07 NS 85.44 ± 17.38 88.46 ± 18.97 < 0.01
Normally distributed data are given as mean ± SD, skewed data are given as median plus [25th, 75th] percentiles. The significance tests are the Mann-Whitney U test 
for normally distributed variables and unpaired t test for normally distributed variables.
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no differences in BMI, waist circumference, WHR, 
lipid profile, glucose, HOMA-I, fT4, and systolic and 
diastolic blood pressure. However, thyroid autoimmun-
ity was associated with elevated TSH and IL-6 levels. 
When we analysed subclinical hypothyroid women 
with and without thyroid autoimmunity, there were 
no significant differences in glucose and lipid profile. 
However, Hashimoto`s subjects were more obese and 
had higher waist circumference, WHR, systolic blood 
pressure, and HOMA-I. The prevalence of metabolic 
syndrome was higher in the T-Abs (+) group. Serum 
concentrations of TSH and IL-6 were higher and fT4 
was lower in T-Abs (+).
Correlations of TSH with variables  
in all postmenopausal women
Among all of the women, serum TSH concentration was 
significantly correlated with BMI, waist circumference, 
WHR, systolic blood pressure, cholesterol, triglycerides, 
and TPO-Abs (Table V). No associations were found 
between TSH and TG-Abs, cHDL, HOMA-I, IL-6 con-
centrations, and diastolic blood pressure.
In the last part of study all subjects were divided for 
quartiles of TSH. Ninety-three women had TSH below 
of 1.82 uIU/mL (lower quartile) and 93 women had TSH 
higher than 4.68 uIU/mL (upper quartile) (Table VI). 
Variables of subjects with upper quartile of TSH were 
compared with variables of lower quartile and we found 
significantly higher BMI, waist circumference, WHR, 
and increased concentration of IL-6, cholesterol, tri-
glycerides, and T-Abs. Concentrations of cHDL and fT4 
were lower. Systolic and diastolic blood pressures were 
also higher. In the lowest quartile 32 women (34.41%) 
had metabolic syndrome; in the highest quartile — 
48 women (51.61%). Then logistic regression analysis 
was performed to calculate the odds ratio (OR) for meta-
bolic syndrome. OR for subjects with TSH > 4.68 uIU/mL 
was 1.35 (95% confidence interval [CI] 1.10–1.60). 
Discussion
Postmenopausal women are predisposed to meta-
bolic syndrome. The decline in ovarian function, weight 
gain, body fat redistribution, and insulin resistance are 
considered as the main causes of this phenomenon. 
The prevalence of metabolic syndrome in women 
after menopause varies in different analyses. In 
a study conducted in Italy [8], metabolic syndrome was 
detected among 27% of postmenopausal women, but 
in the Korean population the prevalence was 58% [9]. 
Table IV. Comparison of clinical and biochemical characteristics of euthyroid and subclinical hypothyroid postmenopausal 
women according to the presence or absence of thyroid antibodies
Tabela IV. Porównanie klinicznych i biochemicznych cech wśród kobiet w eutyreozie i z subkliniczną niedoczynnością tarczycy 
w zależności od obecności lub braku przeciwciał tarczycowych
Euthyroid women (n = 258) Subclinical hypothyroid women (n = 114)
T-Abs (–)
n = 182 (70.54%)
T-Abs (+)
n = 76 (29.46%)
p T-Abs (–)
n = 48 (42.11%)
T-Abs (+)
n = 66 (57.89%)
p
BMI [kg/m2] 28.93 ± 5.14 28.37 ± 4.68 NS 28.90 ± 5.62 30.12 ± 4.61 < 0.01
Waist circumference [cm] 93.73 ± 12.81 92.47 ± 11.43 NS 92.90 ± 13.58 97.84 ± 12.04 < 0.05
WHR 0.86 ± 0.06 92.47 ± 11.43 NS 0.84 ± 0.06 0.89 ± 0.06 < 0.01
Cholesterol [mmol/L] 6.09 ± 1.25 5.97 ± 1.07 NS 6.20 ± 0.95 6.46 ± 1.02 NS
Cholesterol HDL [mmol/L] 1.35 ± 0.36 1.33 ± 0.39 NS 1.34 ± 0.38 1.27 ± 0.38 NS
Triglycerides [mmol/L] 1.65 ± 0.90 1.54 ± 0.67 NS 1.61 ± 0.71 1.83 ± 0.85 NS
Glucose [mg/dL] 91.11 ± 21.10 89.55 ± 14.65 NS 84.48 ± 11.82 88.68 ± 16.63 NS
HOMA-IR 1.037 [0.65; 1.80] 1.00 [0.63; 1.96] NS 0.85 [0.49; 1.75] 1.37 [0.75; 2.80] < 0.01
IL-6 [pg/mL] 2.89 [2.29; 3.4] 3.34 [2.69; 5.35] < 0.01 2.63 [2.12; 3.57] 3.16 [2.36; 4.47] < 0.01
TSH [mIU/mL] 2.01 ± 0.79 2.58 ± 0.95 < 0.01 5.08 ± 0.79 5.70 ± 0.87 <0.01
fT4 [ng/dL] 1.34 ± 0.60 1.30 ± 0.71 NS 1.19 ± 0.67 1.12 ± 0.50 < 0.05
Systolic blood pressure [mm Hg] 125.43 ± 18.28 128.64 ± 29.48 NS 128.54 ± 35.86 138.03 ± 33.46 < 0.01
Diastolic blood pressure [mm Hg] 82.53 ± 11.53 83.32 ± 18.47 NS 85.21 ± 10.64 88.48 ± 12.49 NS
Metabolic syndrome, n (%) 84 (46.15%) 37 (48.68%) NS 17 (35.4%) 39 (59.1%) < 0.05
Normally distributed data are given as mean ± SD, skewed data are given as median plus [25th, 75th] percentiles. The significance tests are the Mann-Whitney U test 
for normally distributed variables and unpaired t test for normally distributed variables.
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Genetic profile, eating habits, age, and social economic 
status influence the frequency of this syndrome. In our 
study 47% of euthyroid and 49% of subclinical hypo-
thyroid women had metabolic syndrome. This is a high 
incidence but it should be noted that the study was 
conducted in the Silesian region, which is an area with 
a growing percentage of obesity in recent years [10], and 
it was carried out at the endocrinology and cardiology 
outpatient clinics, not among a random population. 
It remains unclear if thyroid subclinical dysfunc-
tion accelerates the development of metabolic syn-
drome and whether menopause per se has an effect 
on the thyroid function regardless of aging. It has been 
estimated that 5–23% of postmenopausal women de-
velop subclinical hypothyroidism, and this frequency 
increases with age [11]. Woeber reported that subclini-
cal hypothyroidism occurs in at least 10% of women 
after the age of 60 years [12]. A higher prevalence was 
found in the LAVOS study performed in Puerto Rico in 
2003 among 399 postmenopausal women; in this study 
the occurrence of subjects with TSH > 5.5 mIU/mL was 
24.2% [13]. In the PolSenior Study 7.95% of women 
over 55 years had elevated serum TSH and 23.9% had 
elevated thyroid antibodies [14].
An exact comparison of the occurrence of metabolic 
syndrome in subclinical hypothyroidism is difficult 
because different authors use dissimilar definitions 
of subclinical hypothyroidism. Some authors defined 
subclinical hypothyroidism when concentrations of 
TSH are higher than 3.6 uIU/mL [15], others when it 
was higher than 4.0 uIU/mL [16] or 4.5 uIU/mL [17], and 
still others when it was higher than 5.7 uIU/mL [18]. It 
has recently been discussed whether the upper TSH 
range should be set around 2.5 mIU/L [19]. 
The next problem is that there is special, individual 
set point for pituitary-thyroid axis function, and the 
reference ranges of TSH are altered with age. Most 
cross-sectional and longitudinal studies have shown 
an age-related shift of TSH secretion [20]. Moreover, 
there is a lack of harmonisation of TSH examinations, 
and different methods of assays give analyses variations 
of around 1 mU/L.
Previous studies of the associations between thyroid 
function and metabolic syndrome have given contradic-
tory results. In a study conducted in Mexico there was 
no difference in the prevalence of metabolic syndrome 
between euthyroid and subclinical hypothyroid sub-
Table V. Correlations of serum TSH with selected anthro­
pometric and biochemical parameters in all women
Tabela V. Zależności między TSH i wybranymi antropo­
metrycznymi i biochemnicznymi parametrami wśród 
wszystkich badanych kobiet
Variables Coefficient R Spearman p
BMI 0.19 < 0.001
Waist circumference 0.16 < 0.001
WHR 0.12 < 0.01
Systolic blood pressure 0.24 < 0.05
Cholesterol 0.21 < 0.001
Triglycerides 0.12 < 0.05
TPOAbs 0.31 < 0.001
Table VI. Clinical and biochemical parameters of postmenopausal women, grouped for quartiles of TSH (upper quartile vs. 
lower quartile)
Tabela VI. Kliniczne i biochemiczne parametry wśród kobiet po menopauzie w zależności od kwartyla TSH (górny kwartyl 
vs. dolny kwartyl)
Lower quartile TSH 
TSH < 1.82 uIU/mL (n = 93)
Upper quartile TSH 
TSH > 4.68 uIU/mL (n = 93)
p
BMI [kg/m2] 27.55 ± 4.50 30.55 ± 5.07 < 0.001
Waist circumference [cm] 90.72 ± 11.45 97.48 ± 13.17 < 0.001
WHR 0.84 ± 0.06 0.87 ± 0.06 < 0.01
Cholesterol [mmol/L] 5.84 ± 1.13 6.43 ± 1.05 < 0.001
cHDL [mmol/L] 1.38 ± 0.38 1.26 ± 0.37 < 0.05
Triglycerides [mmol/L] 1.56 ± 0.81 1.78 ± 0.81 < 0.05
Glucose [mg/dL] 89.377 ± 16.49 87.48 ± 15.39 NS
HOMA-IR 0.90 [0.65; 1.64] 1.33 [0.61; 2.51] NS
IL-6 [pg/mL] 2.85 [2.24; 3.33] 2.97 [2.23; 4.29] < 0.05
fT4 [ng/dL] 1.32 ± 0.66 1.14 ± 0.58 < 0.01
TPOAb [IU/mL] 3.42 [1.41; 8.44] 100.93 [12.00; 185.51] < 0.01
TGAb [IU/mL] 15.85 [11.36; 29.54] 47.21 [20.03; 148.02] < 0.001
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jects [3]. However, in a study by Kim et al. TSH in the 
upper normal range (2.5–4.5 mIU/L) was connected 
with a 1.7-fold increased risk of metabolic syndrome 
when compared with TSH in the lower normal range 
(0.3–2.5 mIU/L) [1]. A significant association between 
serum THS and metabolic syndrome was also observed 
in almost 1200 Dutch persons. Subjects with serum TSH 
higher than 2.28 mU/L had significantly increased risk 
of metabolic syndrome compared with subjects with 
serum TSH lower than 1.04 mU/L (OR = 1.68) [2]. 
In our study the prevalence of metabolic syndrome 
was 47% in euthyroid women and 49% in subclinical 
hypothyroid subjects, and the difference did not reach 
any statistical significance. It should be noted that we 
used the definition of subclinical hypothyroidism ac-
cording to NHANES III, with the upper limit for nor-
mal TSH at 4.5 mIU/mL [17]. Although the mean BMIs 
in subclinical hypothyroid and in euthyroid women 
were comparable, waist circumference, WHR, and tri-
glycerides were significantly higher in the subclinical 
hypothyroid group. Moreover, 45.61% of subclinical 
hypothyroid individuals displayed one or two analysed 
abnormalities, and this frequency was higher when 
compared with the euthyroid group (32.17%). Since the 
AHA/NHLBI definition of metabolic syndrome is based 
on the presence of three or more risk factors, women 
with one or two disturbances were not recognised as 
having metabolic syndrome, but their metabolic profile 
was worse. 
We found that TSH levels in the metabolic syndrome 
was higher than in the nonmetabolic group, both in 
the euthyroid and subclinical hypothyroid groups. 
Individual analysis revealed that there is a tendency 
towards an increase in metabolic disturbance rates 
across the quartiles of TSH, and this trend was evident 
in the highest compared with lowest quartile of TSH. 
Postmenopausal women with a serum TSH above 
4.68 uIU/mL had a higher risk of metabolic syndrome 
than women with serum TSH below 1.82 uIU/mL (odds 
ratio 1.35). However, individuals with the upper quartile 
of TSH had significanlty higher BMI, waist circumfer-
ence, and WHR, worse metabolic parameters, and 
higher concentrations of serum IL-6. Because obesity 
is potentially a casual pathway between thyroid func-
tion and metabolic syndrome, we assessed relations 
between TSH, BMI, WHR, and waist circumference, 
and we found positive correlations. Among metabolic 
syndrome components, serum TSH positively corre-
lated also with systolic blood pressure, cholesterol, 
triglycerides, and TPOAbs. 
Our observation about a positive correlation be-
tween BMI and TSH is in agreement with results by 
other researchers [21]. The associations between BMI 
and TSH are complex and include neuroendocrine 
regulation, mainly through leptin-hypothalamic-
pituitary axis and different processes in adipose tis-
sue such as adipogenesis, and lipogenesis/lipolysis. 
Adipocytes secrete leptin, which influences neurons 
in the hypothalamus, regulates appetite and energy 
expenditure, as well as thyreotropic axis and TSH se-
cretion. Thyroid hormones and leptin regulate energy 
balance, thermogenesis, and resting metabolic rate and 
have an impact on the autonomous nervous system. 
Moreover, thyroid hormones and leptin regulate feed-
ing [22]. Recently, Betry et al. hypothesised that the 
increase in TSH observed in obese subjects is the result 
of fat accumulation [23]. Subclinical hypothyroidism 
is associated with lower basal metabolic rate and heat 
production, which can lead to weight gain. Moreover, 
decreased concentrations of thyroid hormones can lead 
to reduced synthesis of sex hormone binding globuline 
and to slower conversion of androgens to estrone. In 
the result, amounts of biologically available androgens 
increase and this could be associated with central adi-
posity, higher blood pressure, and higher rates of lipids 
and glucose disturbances.
In our study we observed a positive association 
between TSH and waist circumference, WHR, and 
serum triglycerides concentrations; this finding is in 
agreement with other studies [24]. It is suggested that 
TSH is involved in the lipid metabolism and promotes 
accumulation of fat in the intraabdominal region, which 
is expressed as increasing WHR and waist circumfer-
ence. In subjects with higher TSH, different processes 
in adipose tissue such as adipogenesis, lipogenesis, 
and lipolysis could be perturbed. Thyrotropin stimu-
lates adipogenesis by activation of preadipocyte dif-
ferentiation, and increases adipocyte hypertrophy by 
triglycerides synthesis in mature adipocytes via TSHR 
expressed in adipose tissue [25]. This might explain 
the pathogenesis of accumulation of visceral adipose 
tissue mass in subclinical hypothyroid women. In an in 
vivo experiment, in a mouse model, mice with elevated 
TSH exhibited a 25% increase in adipose tissue when 
compared to control animals with normal TSH [26]. 
On the other hand, TSH activates hormone-sensitive 
lipase and lipolysis; therefore, elevated levels of TSH 
are connected with raising serum free fatty acids [27]. 
Increased serum FFA concentrations have been observed 
in subclinical hypothyroid patients and could lead to 
insulin resistance [28]. Moreover, TSH promotes hepatic 
lipogenesis, which in turn may cause the development 
of non-alcoholic fatty liver [29]. Felske et al. have shown 
that elevated TSH directly inhibits insulin-stimulated 
intracellular signaling in human adipocytes and insulin 
modulates TSH-stimulated lipolysis [30].
Controversy persists as to whether insulin resistance 
is developing in subclinical hypothyroidism, and the 
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data about this subject are inconsistent. Some studies 
demonstrated that subclinical hypothyroidis leads to 
insulin resistance [31, 32], but other studies did not 
observe this effect [33, 34]. The reason for the differ-
ences in the obtained results may be due to different 
durations and degrees of subclinical hypothyroidism. In 
our analysis we did not find relationships between sub-
clinical hypothyroid status and HOMA index; however, 
the subgroup of subclinical hypothyroid women with 
Hashimoto`s disease was more insulin resistant than 
both the subgroup of subclinical hypothyroid women 
without thyroid antibodies and all euthyroid women. 
However, in our analysis, subclinical hypothyroid 
women positive for thyroid Abs were more obese and 
had higher waist circumference/WHR; therefore, our 
results did not make clear whether autoimmune thy-
roidits has an independent impact on insulin resistance.
We found positive relationships between TSH and 
TPOAbs in all studied women. In chronic thyroiditis 
the mean TSH was higher when compared with sub-
jects without thyroid antibodies, regardless of thyroid 
function. Radetti et al. demonstrated that the elevation 
of TSH levels during follow-up and the progressive 
increase in thyroid autoantibodies were the strongest 
predictive factors of future development of thyroid 
failure in autoimmune thyroiditis patients [35]. The 
evolution from normal stage to hypothyroidism is 
a long process, which consequently, after years, pro-
vides to hypothyroidism. As expected, the prevalence 
of Hashimoto’s thyroditis was higher in the subclinical 
hypothyroid group than in the euthyroid group.
When we investigated the associations between 
thyroid antibodies status and metabolic syndrome, we 
observed higher prevalence of metabolic syndrome in 
Hashimoto’s thyroiditis with subclinical hypothyroid-
ism (p < 0.05), but we could not find such associations 
in euthyroid subjects. Since in our analysis Hashimoto`s 
women with subclinical hypothyroidism had greater 
visceral fat accumulation, our results did not clarify 
whether autoimmune thyroidits has an autonomous 
impact on the development of metabolic syndrome, 
or whether metabolic syndrome is the consequence of 
overweight. It may be that elevated TSH, immunologi-
cal processes, and higher BMI commonly increase the 
risk of metabolic syndrome. Probably a combination of 
different risk factors observed in obese postmenopausal 
women with subclinical hypothyroidism and autoim-
mune thyroiditis generally increase the probability 
of metabolic syndrome development. The results of 
various studies on cardiovascular and metabolic risk in 
Hashimoto’s thyroiditis are inconsistent. An increased 
prevalence of metabolic syndrome in Hashimoto’s 
thyroiditis was reported by Waring et al. [36]. Tamer et 
al. reported that thyroid immunity is associated with 
worsened lipid profile [37]. However, in the analysis 
by LeGrys et al. there was no connection between the 
presence of thyroid antibodies and the risk of myocar-
dial infarction [38]. In a large epidemiological study 
conducted among more than 38 thousand participants 
the risk of CHD mortality and CHD events did not differ 
according to the TPOAb status [39]. 
Autoimmune thyroidits is not only an organ-specific 
disease but it is also a systemic disease with enhanced 
proinflammatory cytokine release. We observed that 
postmenopausal women with antithyroid antibod-
ies exhibit elevated serum IL-6 concentrations when 
compared to women without antibodies, regardless of 
thyroid function. Our findings are in agreement with 
those obtained by Taddei et al. [6]. IL-6 is produced by 
adipocytes and adipose-tissue macrophages. Elevated 
concentration of this cytokine is the marker of endothe-
lial dysfunction, which is an early step in the develop-
ment of atherosclerosis. Impaired endothelial function 
and reduced nitric oxide availability have been shown 
in subjects with thyroid antibodies. We also found that 
IL-6 concentrations are elevated in subjects with higher 
TSH, and our results are in agreement with several stud-
ies that have reported low-grade chronic inflammation 
in subclinical hypothyroidism. It has been shown that 
TSH upregulates IL-6 and MCP-1 mRNA expression 
and release from adipose tissue. Serum concentrations 
of proinflammatory cytokines such as IL-6 and MCP-1 
have been found to be elevated in chronic thyroidits 
with mild hypothyroidism; therefore, higher levels of 
TSH could be pro-inflammatory stimuli of adipocytes 
[40]. It has been shown that elevated TSH through 
TSHR is expressed in microvascular endothelial cells 
and attenuates NO and prostacyclin release [41]. 
In this work we have found that relationships 
between subclinical hypothyroid dysfunction and 
metabolic syndrome include the associations with 
obesity and different metabolic disturbances. Subclini-
cal hypothyroidism, especially in the course of chronic 
thyroiditis, is associated with weight gain, dyslipidae-
mia, and insulin resistance, and combination of multiple 
factors can increase the risk of metabolic syndrome.
Our study has the following limitation: a relatively 
small number of subclinical hypothyroid women with-
out antithyroid antibodies. Another limitation is the 
known fact that elevated levels of antibodies against 
thyroid peroxidase and/or thyroglobulin are not pre-
sent in all patients with chronic thyroiditis. Although 
thyroid antibodies provide the most specific laboratory 
evidence of immunological thyroiditis, their occurrence 
is not mandatory. The next restraint is that in our study 
the diagnosis of Hashimoto’s thyroiditis was made by 
elevated TPOAb and/or TGAb concentrations. However, 
some endocrinologists consider TPOAb concentrations 
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more specific for thyroidits than TGAb, and they assume 
that TGAb is unnecessary for diagnosis of AIT. There-
fore, our conclusion about the effect of autoimmune 
thyroiditis on metabolic syndrome only in subclinical 
hypothyroid women appears to be limited, and further 
studies are necessary. 
Conclusions
1. Our study confirms that metabolic syndrome in both 
euthyroid and subclinical hypothyroid women is 
connected with obesity, visceral fat accumulation, 
and higher TSH and IL-6 concentrations. 
2. Immune thyroiditis is associated with higher TSH 
and IL-6 levels. Obese subclinical hypothyroid 
women with Hashimoto’s thyroditis have a higher 
prevalence of metabolic syndrome compared with 
subclinical hypothyroid women without thyroid 
autoimmunity. 
3. It is possible that in the crosstalking between sub-
clinical hypothyroidism and metabolic syndrome, 
enhanced proinflammatory cytokine release in the 
course of immunological thyroiditis plays a role. 
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